Analysts recommend GSK after Teva announces Advair generic delay
The delay for the generic version of UK pharma major GlaxoSmithKline’s (LSE: GSK) Advair (fluticasone and salmeterol) coupled with the advances in the company’s GSK2606414 product in Alzheimer’s disease has prompted analysts at Panmure Gordon to point to today’s share price level as good entry level to the stock.
They pointed to Israel-based generics manufacturer Teva Pharmaceutical Industries (NYSE: TEVA) which said it did not expect to see generic copies of Advair until 2018 at the earliest. They added that, with data from darapladib pending this quarter, GSK stock could be on its way up.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze